Drug intelligence / Profile preview

KetoVie Peptide

Development stage: Unknown
Lead developer: Cambrooke Therapeutics
Modality: Peptides
Administration: Oral, Enteral

Overview

KetoVie Peptide is a ketogenic medical food product developed by Cambrooke Therapeutics for the dietary management of intractable epilepsy and other conditions requiring ketogenic therapy in patients aged one year and older. It is a nutritionally complete, ready-to-use enteral formula with a 4:1 ketogenic ratio (fat to net carbohydrate plus protein). The product features extensively hydrolyzed whey protein as its protein source, making it suitable for individuals with impaired gastrointestinal function or intolerance to whole proteins. It is enriched with medium-chain triglycerides (MCT), docosahexaenoic acid (DHA), selenium, and carnitine, and is designed for administration under medical supervision, typically via tube feeding.

Brand names: KetoVie Peptide

Beyond the preview

Go deeper on KetoVie Peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KetoVie Peptide.

Explore the full profile